Blood Coagulants Market Opportunities, Forecast, Size, Competitive Analysis till 2031

Coverage: by Drug class (Non-VKA Oral Anticoagulants (NOACs), Heparin and Low-molecular-weight heparin (LMWH), Vitamin K Antagonist, Others); Route of administration (Oral, Injectable); Bleeding disorder type (Hemophilia A, Hemophilia B, von Willebrand disease (VWD), Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2023 | Base Year: 2024 | Forecast Period: 2025-2031
  • Status : Data Released
  • Report Code : TIPRE00004416
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : January 27, 2025
Blood Coagulants Market Opportunities, Forecast, Size, Competitive Analysis till 2031
Report Date: January 27, 2025   |   Report Code: TIPRE00004416 Email: sales@theinsightpartners.com

2024 Market Size

US$ 13.63 Bn

Base year value

2031 Forecast

US$ 21.6 Bn

Projected by 2031

CAGR 2025-2031

6.8 %

Growth rate

Addressable Market

US$ 125.21 Bn

(2025-2031)

The Blood Coagulants Market size is expected to reach US$ 21.6 Billion by 2031. The market is anticipated to register a CAGR of 6.8% during 2025-2031.

The Blood Coagulants Market report covers analysis by Drug class (Non-VKA Oral Anticoagulants (NOACs), Heparin and Low-molecular-weight heparin (LMWH), Vitamin K Antagonist, Others); Route of administration (Oral, Injectable); Bleeding disorder type (Hemophilia A, Hemophilia B, von Willebrand disease (VWD), Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Blood Coagulants Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Blood Coagulants Market Segmentation Drug class

  1. Non-VKA Oral Anticoagulants
  2. Heparin and Low-molecular-weight heparin
  3. Vitamin K Antagonist
  4. Others

Route of administration

  1. Oral
  2. Injectable

Bleeding Disorder Type

  1. Hemophilia A
  2. Hemophilia B
  3. von Willebrand disease
  4. Others

Geography

  1. North America
  2. Europe
  3. Asia-Pacific
  4. South and Central America
  5. Middle East and Africa

Market Assessment and Insights

  • Global market for Blood Coagulants was valued at US$ 13.63 Billion in 2024
  • Annual market size is expected to reach US$ 21.60 Billion by 2031
  • Total addressable market (TAM) during 2025-2031 is projected to reach approximately US$ 125.21 Billion
  • Market is anticipated to register a CAGR of 6.8% during the forecast period
  • The United States represents a key market, supported by Increasing Prevalence of Hemophilia and Other Bleeding Disorders, Surgical Procedures and Trauma Care, Aging Population, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Expansion of Patient Support Programs, Research into Novel Coagulants, Collaborations and Partnerships are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Aspen Holdings, Bayer AG, Bristol-Myers Squibb Company, Baxter International Inc., Daiichi Sankyo Company, Grifols International SA, Limited, GlaxoSmithKline Plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Novo Nordisk A/S, Pfizer, Inc., while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Blood Coagulants Market: Strategic Insights

blood-coagulants-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Blood Coagulants Market Growth Drivers

  1. Increasing Prevalence of Hemophilia and Other Bleeding Disorders:
    The rising number of individuals diagnosed with hemophilia, von Willebrand disease, and other bleeding disorders is significantly driving the demand for blood coagulants.
  2. Surgical Procedures and Trauma Care:
    Surgical procedures, especially major surgeries, and trauma cases often require blood coagulants to control bleeding, pushing the market for coagulation treatments forward.
  3. Aging Population:
    The growing elderly population, more prone to health complications such as blood clotting disorders, is increasing the need for blood coagulants.

Blood Coagulants Market Future Trends

  1. Preference for Recombinant Coagulants:
    Recombinant blood coagulants are gaining popularity due to their high safety profile, lower risk of blood-borne infections, and more controlled production methods.
  2. Shift Toward Home Treatment:
    Home therapy for hemophilia and other bleeding disorders, where patients can self-administer coagulant treatments, is becoming a growing trend, offering greater convenience and improving quality of life.
  3. Introduction of Long-Acting Coagulants:
    Advances in the development of long-acting blood coagulants are improving the treatment experience for patients, reducing the frequency of injections and enhancing patient compliance.

Blood Coagulants Market Opportunities

  1. Expansion of Patient Support Programs:
    Manufacturers are increasingly offering patient assistance and support programs to improve treatment access, adherence, and overall patient outcomes, expanding the market potential.
  2. Research into Novel Coagulants:
    Ongoing research in developing new coagulants, including oral therapies and more effective treatments for rare bleeding disorders, presents significant opportunities for innovation in the market.
  3. Collaborations and Partnerships:
    Strategic collaborations between pharmaceutical companies, biotech firms, and research institutions can enhance the development and commercialization of innovative blood coagulants, further driving market growth.

Blood Coagulants Market Report Scope

Report Attribute Details
Market size in 2024 US$ 13.63 Billion
Market Size by 2031 US$ 21.6 Billion
Global CAGR (2025 - 2031) 6.8%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Drug class
  • Non-VKA Oral Anticoagulants
  • Heparin and Low-molecular-weight heparin
  • Vitamin K Antagonist
  • Others
By Route of administration
  • Oral
  • Injectable
By Bleeding Disorder Type
  • Hemophilia A
  • Hemophilia B
  • von Willebrand disease
  • Others
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Aspen Holdings
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Baxter International Inc.
  • Daiichi Sankyo Company
  • Grifols International SA, Limited
  • GlaxoSmithKline Plc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Novo Nordisk A/S
  • Pfizer, Inc.

Blood Coagulants Market Players Density: Understanding Its Impact on Business Dynamics

The Blood Coagulants Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

blood-coagulants-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Blood Coagulants Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Blood Coagulants Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Key companies of this market are: Aspen Holdings, Bayer AG, Bristol-Myers Squibb Company, Baxter International Inc., Daiichi Sankyo Company, Grifols International SA, Limited, GlaxoSmithKline Plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc), Novo Nordisk A/S, Pfizer, Inc.

Key future trends in this market are - Innovative Drug Development, Growing Hemophilia Prevalence, Prophylactic Treatment Adoption

The Blood Coagulants Market is estimated to witness a CAGR of 6.8% from 2025 to 2031.

The major factors driving the market are: Increased prevalence of blood disorders, Technological advancements in hemostasis, Growing surgical procedures worldwide
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA